Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1988 1
1989 1
1995 3
1996 3
1997 4
1998 1
2000 1
2001 3
2002 1
2003 1
2004 3
2005 3
2006 4
2008 6
2009 5
2010 3
2011 3
2012 7
2013 7
2014 9
2015 5
2016 4
2017 7
2018 8
2019 12
2020 9
2021 10
2022 15
2023 15
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting.
Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, Fabiani E, Divona M, Travaglini S, Pascale MR, Awada H, Durmaz A, Visconte V, Della Porta MG, Venditti A, Maciejewski JP, Gurnari C, Voso MT. Attardi E, et al. Blood Adv. 2023 Sep 12;7(17):5122-5131. doi: 10.1182/bloodadvances.2023010173. Blood Adv. 2023. PMID: 37327116 Free PMC article.
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar SJ, Klisovic RB, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD. Döhner K, et al. Blood. 2020 Jan 30;135(5):371-380. doi: 10.1182/blood.2019002697. Blood. 2020. PMID: 31826241 Free PMC article.
Clonal evolution in therapy-related neoplasms.
Fabiani E, Falconi G, Fianchi L, Criscuolo M, Ottone T, Cicconi L, Hohaus S, Sica S, Postorino M, Neri A, Lionetti M, Leone G, Lo-Coco F, Voso MT. Fabiani E, et al. Oncotarget. 2017 Feb 14;8(7):12031-12040. doi: 10.18632/oncotarget.14509. Oncotarget. 2017. PMID: 28076841 Free PMC article.
Therapy-related myeloid neoplasms (t-MN) may occur as a late effect of cytotoxic therapy for a primary malignancy or autoimmune diseases in susceptible individuals. We studied the development of somatic mutations in t-MN, using a collection of follow-up samples from …
Therapy-related myeloid neoplasms (t-MN) may occur as a late effect of cytotoxic therapy for a primary malignancy or autoimmune disea …
Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways.
Ottone T, Silvestrini G, Piazza R, Travaglini S, Gurnari C, Marchesi F, Nardozza AM, Fabiani E, Attardi E, Guarnera L, Divona M, Ricci P, Irno Consalvo MA, Ienzi S, Arcese R, Biagi A, Fiori L, Novello M, Mauriello A, Venditti A, Anemona L, Voso MT. Ottone T, et al. Leukemia. 2023 Dec;37(12):2383-2394. doi: 10.1038/s41375-023-02054-0. Epub 2023 Oct 6. Leukemia. 2023. PMID: 37803061
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N, Jahn E, Saadati M, Bullinger L, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Ehninger G, Heuser M, Ganser A, Pallaud C, Gathmann I, Krzykalla J, Benner A, Bloomfield CD, Thiede C, Stone RM, Döhner H, Döhner K. Jahn N, et al. Leukemia. 2022 Sep;36(9):2218-2227. doi: 10.1038/s41375-022-01650-w. Epub 2022 Aug 3. Leukemia. 2022. PMID: 35922444 Free PMC article. Clinical Trial.
From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression.
Gurnari C, Fabiani E, Falconi G, Travaglini S, Ottone T, Cristiano A, Voso MT. Gurnari C, et al. Biology (Basel). 2021 Feb 6;10(2):128. doi: 10.3390/biology10020128. Biology (Basel). 2021. PMID: 33562056 Free PMC article. Review.
Invariant patterns of genes seem to contribute to the arising of t-MN cases, with differences regarding the type of treatment received. Here, we review the principal studies concerning CH, the relationship with myeloid progression and the mechanisms of secondary t-M …
Invariant patterns of genes seem to contribute to the arising of t-MN cases, with differences regarding the type of treatment receive …
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
Perrone S, Ottone T, Zhdanovskaya N, Molica M. Perrone S, et al. Cancer Drug Resist. 2023 Apr 28;6(2):223-238. doi: 10.20517/cdr.2022.130. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37457126 Free PMC article. Review.
Finally, several ongoing efforts to overcome resistance to FLT3-inhibitors will be presented: new generation FLT3 inhibitors in monotherapy or combined with standard chemotherapy, hypomethylating drugs, or IDH1/2 inhibitors, Bcl2 inhibitors; novel anti-human FLT3 monoclonal antib …
Finally, several ongoing efforts to overcome resistance to FLT3-inhibitors will be presented: new generation FLT3 inhibitors in monotherapy …
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs' patients.
Catalano G, Zaza A, Banella C, Pelosi E, Castelli G, de Marinis E, Smigliani A, Travaglini S, Ottone T, Divona M, Del Principe MI, Buccisano F, Maurillo L, Ammatuna E, Testa U, Nervi C, Venditti A, Voso MT, Noguera NI. Catalano G, et al. Leukemia. 2023 Aug;37(8):1600-1610. doi: 10.1038/s41375-023-01946-5. Epub 2023 Jun 22. Leukemia. 2023. PMID: 37349598
133 results